The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
Open accessAbstract
BACKGROUND: Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the recommendations for the use of tumour next-generation sequencing (NGS) for patients with advanced cancers in routine practice. METHODS: The group discussed the clinical impact of tumour NGS in guiding treatment decision using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) considering cost-effectiveness and accessibility. RESULTS: As for 2020 recommendations, ESMO recommends running tumour NGS in advanced non-squamous non-small-cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma, and ovarian cancer. Moreover, it is recommended to carry out tumour NGS in clinical research centres and under specific circumstances discussed with patients. In this updated report, the consensus within the group has led to an expansion of the recommendations to encompass patients with advanced breast cancer and rare tumours such as gastrointestinal stromal tumours, sarcoma, thyroid cancer, and cancer of unknown primary. Finally, ESMO recommends carrying out tumour NGS to detect tumour-agnostic alterations in patients with metastatic cancers where access to matched therapies is available. CONCLUSION: Tumour NGS is increasingly expanding its scope and application within oncology with the aim of enhancing the efficacy of precision medicine for patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Self-citationDemetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citationMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Self-citationTalazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Self-citationDemetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Self-citationMosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Self-citationMarcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176
Clonal hematopoiesis in human aging and disease
Jaiswal, S., & Ebert, B. L. (2019) · Science · doi:10.1126/science.aan4673 · Cited by 1,156
Abou-Alfa, G. K., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V., Borad, M. J., Bridgewater, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,116
Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,099
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Midha, A., Dearden, S. P., & McCormack, R. (2015) · Europe PMC (PubMed Central) · Cited by 1,050
Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Dei Tos, A. P., Kunkler, I., Otter, R., Licitra, L., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 809
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Self-citationEfficacy of Selpercatinib in RET -Altered Thyroid Cancers
Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005651 · Cited by 790
Self-citationVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Self-citationBidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
Krop, I. E., Kim, S.-B., González-Martín, A., LoRusso, P. M., Ferrero, J.-M., Smitt, M., Yu, R., Leung, A. C. F., & Wildiers, H. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70178-0 · Cited by 724
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5009 · Cited by 693
Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H. I., Ahn, J. S., Shaw, A. T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.478 · Cited by 686
Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 655
de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, J. W., Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206834 · Cited by 613
Self-citationSaura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00147 · Cited by 604
Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz131 · Cited by 576
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Self-citationLin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00775 · Cited by 544
Subbiah, V., Lassen, U., Élez, E., Italiano, A., Curigliano, G., Javle, M., de Braud, F., Prager, G. W., Greil, R., Stein, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30321-1 · Cited by 533
Pan-cancer landscape of homologous recombination deficiency.
Nguyen, L., W. M. Martens, J., Van Hoeck, A., & Cuppen, E. (2020) · Nature communications · doi:10.1038/s41467-020-19406-4 · Cited by 532
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2208470 · Cited by 527
Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E., Comber, H., Dimitrova, N., Leinonen, M. K., Siesling, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30445-x · Cited by 516
DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01549 · Cited by 511
Tung, N. M., Robson, M. E., Ventz, S., Santa-Maria, C. A., Nanda, R., Marcom, P. K., Shah, P. D., Ballinger, T. J., Yang, E. S., Vinayak, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02151 · Cited by 508
Self-citationBenayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R., Won, H., Chang, J., Halpenny, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 484
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449
Subbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J., Takeda, M., Ohe, Y., Khan, S., Ohashi, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00541-1 · Cited by 449
González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R. E., Pothuri, B., Ray-Coquard, I., Tan, D. S. P., Bellet, E., Oaknin, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.011 · Cited by 449
Self-citationPassaro, A., Wang, J., Wang, Y., Lee, S.-H., Melosky, B., Shih, J.-Y., Wang, J., Azuma, K., Juan-Vidal, O., Cobo, M., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.117 · Cited by 440
Gounder, M., Schöffski, P., Jones, R. L., Agulnik, M., Cote, G. M., Villalobos, V. M., Attia, S., Chugh, R., Chen, T. W.-W., Jahan, T., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30451-4 · Cited by 427
Javle, M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou-Alfa, G. K., George, B., Hainsworth, J., Meric-Bernstam, F., Swanton, C., Sweeney, C. J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00336-3 · Cited by 425
Self-citationSiena, S., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 422
Blay, J.-Y., Serrano, C., Heinrich, M. C., Zalcberg, J., Bauer, S., Gelderblom, H., Schöffski, P., Jones, R. L., Attia, S., D'Amato, G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30168-6 · Cited by 416
Self-citationSotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
Rutkowski, P., Van Glabbeke, M., Rankin, C. J., Ruka, W., Rubin, B. P., Debiec-Rychter, M., Lazar, A., Gelderblom, H., Sciot, R., Lopez-Terrada, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7899 · Cited by 398
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Drilon, A., Clark, J. W., Weiss, J., Ou, S.-H. I., Camidge, D. R., Solomon, B. J., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0716-8 · Cited by 395
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
Abou-Alfa, G. K., Chan, S. L., Kudo, M., Lau, G., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Dao, T. V., De Toni, E. N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.379 · Cited by 388
Brose, M. S., Cabanillas, M. E., Cohen, E. E. W., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30166-8 · Cited by 388
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C. H., Han, J.-Y., Hochmair, M. J., Lee, K. H., Delmonte, A., Garcia Campelo, M. R., Kim, D.-W., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.035 · Cited by 388
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Zhou, C., Tang, K.-J., Cho, B. C., Liu, B., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., Goldman, J. W., Sabari, J. K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306441 · Cited by 381
Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358
Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., Kao, S., Lin, C.-C., Bauer, T. M., Clancy, J. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30655-2 · Cited by 358
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Boran, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.014 · Cited by 357
Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.037 · Cited by 348
Rugo, H. S., Lerebours, F., Ciruelos, E., Drullinsky, P., Ruiz-Borrego, M., Neven, P., Park, Y. H., Prat, A., Bachelot, T., Juric, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00034-6 · Cited by 345
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J.-Y., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02321-8 · Cited by 343
Rugo, H. S., Im, S.-A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escrivá-de-Romaní, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7932 · Cited by 343
SMARCB1/INI1 Tumor Suppressor Gene Is Frequently Inactivated in Epithelioid Sarcomas
Modena, P., Lualdi, E., Facchinetti, F., Galli, L., Teixeira, M. R., Pilotti, S., & Sozzi, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3050 · Cited by 335
Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., Massard, C., Matsubara, N., Alekseev, B., Parnis, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00580-8 · Cited by 335
Heinrich, M. C., Jones, R. L., von Mehren, M., Schöffski, P., Serrano, C., Kang, Y.-K., Cassier, P. A., Mir, O., Eskens, F., Tap, W. D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30269-2 · Cited by 320
Self-citationde Bono, J. S., De Giorgi, U., Rodrigues, D. N., Massard, C., Bracarda, S., Font, A., Arranz Arija, J. A., Shih, K. C., Radavoi, G. D., Xu, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0981 · Cited by 311
Salama, A. K. S., Li, S., Macrae, E. R., Park, J.-I., Mitchell, E. P., Zwiebel, J. A., Chen, H. X., Gray, R. J., McShane, L. M., Rubinstein, L. V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00762 · Cited by 308
Harding, J. J., Fan, J., Oh, D.-Y., Choi, H. J., Kim, J. W., Chang, H.-M., Bao, L., Sun, H.-C., Macarulla, T., Xie, F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00242-5 · Cited by 291
Papadimitrakopoulou, V. A., Mok, T. S., Han, J.-Y., Ahn, M.-J., Delmonte, A., Ramalingam, S. S., Kim, S. W., Shepherd, F. A., Laskin, J., He, Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2100 · Cited by 275
Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazieres, J., Kim, T. M., Quoix, E., Souquet, P.-J., Barlesi, F., Baik, C., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.011 · Cited by 272
Self-citationStrickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00150-x · Cited by 259
Horn, L., Wang, Z., Wu, G., Poddubskaya, E., Mok, T., Reck, M., Wakelee, H., Chiappori, A. A., Lee, D. H., Breder, V., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3523 · Cited by 252
Reiss, K. A., Mick, R., O'Hara, M. H., Teitelbaum, U., Karasic, T. B., Schneider, C., Cowden, S., Southwell, T., Romeo, J., Izgur, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00003 · Cited by 248
Subbiah, V., Cassier, P. A., Siena, S., Garralda, E., Paz-Ares, L., Garrido, P., Nadal, E., Vuky, J., Lopes, G., Kalemkerian, G. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01931-y · Cited by 247
Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01604 · Cited by 244
Ross, J. S., Wang, K., Gay, L., Otto, G. A., White, E., Iwanik, K., Palmer, G., Yelensky, R., Lipson, D. M., Chmielecki, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.216 · Cited by 244
Ciampi, R., Romei, C., Ramone, T., Prete, A., Tacito, A., Cappagli, V., Bottici, V., Viola, D., Torregrossa, L., Ugolini, C., et al. (2019) · iScience · doi:10.1016/j.isci.2019.09.030 · Cited by 239
Solomon, B. J., Bauer, T. M., Mok, T. S. K., Liu, G., Mazieres, J., de Marinis, F., Goto, Y., Kim, D.-W., Wu, Y.-L., Jassem, J., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00437-4 · Cited by 236
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
Zhou, C., Solomon, B., Loong, H. H., Park, K., Pérol, M., Arriola, E., Novello, S., Han, B., Zhou, J., Ardizzoni, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309457 · Cited by 233
Demetri, G. D., De Braud, F., Drilon, A., Siena, S., Patel, M. R., Cho, B. C., Liu, S. V., Ahn, M.-J., Chiu, C.-H., Lin, J. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3597 · Cited by 223
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Krämer, A., Bochtler, T., Pauli, C., Baciarello, G., Delorme, S., Hemminki, K., Mileshkin, L., Moch, H., Oien, K., Olivier, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.11.013 · Cited by 221
Self-citationChi, K. N., Sandhu, S., Smith, M. R., Attard, G., Saad, M., Olmos, D., Castro, E., Roubaud, G., Pereira de Santana Gomes, A. J., Small, E. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.06.009 · Cited by 217
Self-citationDrilon, A., Subbiah, V., Gautschi, O., Tomasini, P., de Braud, F., Solomon, B. J., Shao-Weng Tan, D., Alonso, G., Wolf, J., Park, K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00393 · Cited by 213
Pant, S., Schuler, M., Iyer, G., Witt, O., Doi, T., Qin, S., Tabernero, J., Reardon, D. A., Massard, C., Minchom, A., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00275-9 · Cited by 213
Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer
Hadoux, J., Elisei, R., Brose, M. S., Hoff, A. O., Robinson, B. G., Gao, M., Jarzab, B., Isaev, P., Kopeckova, K., Wadsley, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309719 · Cited by 210
Lu, S., Fang, J., Li, X., Cao, L., Zhou, J., Guo, Q., Liang, Z., Cheng, Y., Jiang, L., Yang, N., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00084-9 · Cited by 207
Valero, C., Lee, M., Hoen, D., Zehir, A., Berger, M. F., Seshan, V. E., Chan, T. A., & Morris, L. G. T. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7684 · Cited by 206
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V., Ferraro, R. A., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30496-0 · Cited by 204
Arrieta, O., Cardona, A. F., Martín, C., Más-López, L., Corrales-Rodríguez, L., Bramuglia, G., Castillo-Fernandez, O., Meyerson, M., Amieva-Rivera, E., Campos-Parra, A. D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000481 · Cited by 193
Schöffski, P., Šufliarský, J., Gelderblom, H. A. J., Blay, J., Strauss, S. J., Stacchiotti, S., Rutkowski, P. L., Lindner, L. H., Leahy, M. G., Italiano, A., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30116-4 · Cited by 188
The burden of rare cancers in the United States
DeSantis, C. E., Kramer, J. L., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21400 · Cited by 186
Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C. S., Tan, D. S. W., Lee, D. H., Misch, D., Garralda, E., Kim, D.-W., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.002 · Cited by 186
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K., Van Tine, B. A., Chugh, R., Cranmer, L., Gordon, E. M., Hornick, J. L., Du, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01728 · Cited by 183
Hartmaier, R. J., Markovets, A. A., Ahn, M. J., Sequist, L. V., Han, J.-Y., Cho, B. C., Yu, H. A., Kim, S.-W., Yang, J. C.-H., Lee, J.-S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0586 · Cited by 172
Bradford, D., Larkins, E., Mushti, S. L., Rodriguez, L., Skinner, A. M., Helms, W. S., Price, L. S. L., Zirkelbach, J. F., Li, Y., Liu, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3558 · Cited by 171
Schram, A. M., Odintsov, I., Espinosa-Cotton, M., Khodos, I., Sisso, W. J., Mattar, M. S., Lui, A. J. W., Vojnic, M., Shameem, S. H., Chauhan, T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1119 · Cited by 171
Fizazi, K. S., Azad, A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., Jones, R. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02704-x · Cited by 169
Kuzbari, Z., Bandlamudi, C., Loveday, C., Garrett, A., Mehine, M. M., George, A. J., Hanson, H., Snape, K. M. G., Kulkarni, A., Allen, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.003 · Cited by 160
Self-citationBiomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Carreira, S., Porta, N., Arce-Gallego, S., Seed, G., Llop-Guevara, A., Bianchini, D., Rescigno, P., Paschalis, A., Bertan, C., Baker, C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0007 · Cited by 159
Self-citationMonk, B. J., Grisham, R. N., Banerjee, S. N., Kalbacher, E., Mirza, M. R., Romero, I., Vuylsteke, P., Coleman, R. L., Hilpert, F., Oza, A. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01164 · Cited by 158
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer
Filetti, S., Durante, C., Hartl, D. M., Leboulleux, S., Locati, L. D., Newbold, K. L., Papotti, M. G., & Berruti, A. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.009 · Cited by 151
Gruber, J. J., Afghahi, A., Timms, K. M., DeWees, A., Gross, W., Aushev, V. N., Wu, H.-T., Balcioglu, M., Sethi, H., Scott, D., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00439-1 · Cited by 147
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
Luca, A. D., Abate, R. E., Rachiglio, A. M., Maiello, M. R., Esposito, C., Schettino, C., Izzo, F., Nasti, G., & Normanno, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186856 · Cited by 146
Self-citationLee, C., Chon, H. J., Cheon, J., Lee, M. A., Im, H.-S., Jang, J.-S., Kim, M. H., Park, S., Kang, B., Hong, M., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00335-1 · Cited by 142
Subbiah, V., Gainor, J. F., Oxnard, G. R., Tan, D. S.-W., Owen, D. H., Cho, B. C., Loong, H. H.-F., McCoach, C. E., Weiss, J. M., Kim, Y. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0800 · Cited by 141
Riely, G. J., Smit, E. F., Ahn, M., Felip, E., Ramalingam, S. S., Tsao, A. S., Johnson, M. L., Gelsomino, F., Esper, R. M., Nadal, E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00774 · Cited by 138
Robson, M. E., Im, S., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Tung, N., Armstrong, A. C., Dymond, M., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.031 · Cited by 136
Self-citationPan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers
Subbiah, V., Puzanov, I. J., Blay, J., Chau, I., Lockhart, A. C., Raje, N. S., Wolf, J., Baselga, J. M., Meric‐Bernstam, F., Roszik, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1265 · Cited by 133
Self-citationAbida, W. M., Campbell, D. C., Patnaik, A., Bryce, A. H., Shapiro, J. D., Bambury, R. M., Zhang, J., Burke, J. M., Castellano, D., Pous, A. F., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.05.021 · Cited by 128
Tan, A. C., Lai, G. G. Y., Tan, G. S., Poon, S. Y., Doble, B., Lim, T. H., Aung, Z. W., Takano, A. M., Tan, W. L., Ang, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.022 · Cited by 123
Nakamura, Y., Mizuno, N., Sunakawa, Y., Canon, J.-L. R., Galsky, M. D., Hamilton, E. P., Hayashi, H., Jérusalem, G., Kim, S. T., Lee, K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00606 · Cited by 123
Kang, Y., George, S., Jones, R. L., Rutkowski, P. L., Shen, L., Mir, O., PATEL, S. R., Zhou, Y., von Mehren, M., Hohenberger, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00217 · Cited by 119
Smyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J. M., Shapiro, G. I., Juric, D., Mayer, I. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0966 · Cited by 118
Self-citationKim, J., Bradford, D., Larkins, E. A., Pai-Scherf, L. H., Chatterjee, S., Mishra-Kalyani, P. S., Wearne, E., Helms, W. S., Ayyoub, A., Bi, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0967 · Cited by 118
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
Drilon, A., Chiu, C.-H., Fan, Y., Cho, B. C., Lu, S., Ahn, M.-J., Krebs, M. G., Liu, S. V., John, T., Otterson, G. A., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100332 · Cited by 113
Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., Meric‐Bernstam, F., Wang, Y., Levy, J., Grindheim, J. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0450 · Cited by 112
Self-citationAntitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
Harding, J. J., Piha-Paul, S. A., Shah, R. H., Murphy, J., Cleary, J. M., Shapiro, G. I., Quinn, D. I., Braña, I., Moreno, V., Borad, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36399-y · Cited by 110
Self-citationEffect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
Kalinsky, K. M., Hong, F., McCourt, C. K., Sachdev, J. C., Mitchell, E. P., Zwiebel, J. A., Doyle, L. A., McShane, L. M., Li, S., Gray, R. J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6741 · Cited by 102
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
Rousseau, B., Bièche, I., Pasmant, É., Hamzaoui, N., Leulliot, N., Michon, L., de Reyniès, A., Attignon, V., Foote, M. B., Masliah‐Planchon, J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0521 · Cited by 93
Self-citationNeumann, O., Burn, T. C., Allgäuer, M., Ball, M., Kirchner, M., Albrecht, T., Volckmar, A., Beck, S., Endris, V., Goldschmid, H., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01908-1 · Cited by 89
Self-citationOpen-label phase II study of the efficacy of nivolumab for cancer of unknown primary
Tanizaki, J., Yonemori, K., Akiyoshi, K., Minami, H., Ueda, H., Takiguchi, Y., Miura, Y., Segawa, Y., Takahashi, S. I., Iwamoto, Y., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.009 · Cited by 87
Meric‐Bernstam, F., Makker, V., Oaknin, A., Oh, D., Banerjee, S. N., González-Martı́n, A., Jung, K. H., Lugowska, I. A., Manso, L., Manzano, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.17_suppl.lba3000 · Cited by 86
Self-citationRoss, J. S., Sokol, E. S., Moch, H., Mileshkin, L., Baciarello, G., Losa, F., Beringer, A., Thomas, M., Elvin, J. A., Ngo, N., et al. (2020) · The Oncologist · doi:10.1002/onco.13597 · Cited by 81
Self-citationBekaii‐Saab, T., Spira, A. I., Yaeger, R. D., Buchschacher, G. L., McRee, A. J., Sabari, J. K., Johnson, M. L., Barve, M. A., Hafez, N., Velastegui, K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.519 · Cited by 80
Möhrmann, L., Werner, M., Oleś, M., Möck, A., Uhrig, S., Jahn, A., Kreutzfeldt, S., Fröhlich, M., Hutter, B., Paramasivam, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31866-4 · Cited by 75
Self-citationBauml, J. M., Cho, B. C., Park, K., Lee, K. H., Cho, E. K., Kim, D., Kim, S., Haura, E. B., Sabari, J. K., Sanborn, R. E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9006 · Cited by 69
Schram, A. M., Goto, K., Kim, D., Martín-Romano, P., Ou, S. I., O'Kane, G. M., O'Reilly, E. M., Umemoto, K., Duruisseaux, M., Neuzillet, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.105 · Cited by 65
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
Terraf, P., Pareja, F. G., Brown, D. N., Ceyhan‐Birsoy, O., Misyura, M., Rana, S., O'Reilly, E. M., Carlo, M. I., Aghajanian, C. A., Liu, Y. L., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.006 · Cited by 61
Self-citationYang, J. C., Schüler, M., Popat, S., Miura, S., Park, K., Passaro, A., de Marinis, F., Solca, F., Märten, A., & Kim, E. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834704 · Cited by 61
Kazdal, D. N., Hofman, V., Christopoulos, P., Ilié, M., Stenzinger, A., & Hofman, P. M. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23022 · Cited by 60
Self-citationZou, D., Ye, W., Hess, L. M., Bhandari, N. R., Ale-Ali, A., Foster, J., Quon, P., & Harris, M. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.04.010 · Cited by 58
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Singh, H., Keller, R. B., Kapner, K. S., Dilly, J., Raghavan, S., Yuan, C., Cohen, E. F., Tolstorukov, M. Y., Andrews, E., Brais, L. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3930 · Cited by 58
Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor Malignancies
Marshall, C. H., Gondek, L. P., Luo, J., & Antonarakis, E. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0985 · Cited by 57
Schram, A. M., O'Reilly, E. M., O'Kane, G. M., Goto, K., Kim, D., Neuzillet, C., Martín-Romano, P., Duruisseaux, M., Nagasaka, M., Rodon, J. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.3003 · Cited by 54
Hodgson, D., Lai, Z., Dearden, S. P., Barrett, J. C., Harrington, E. A., Timms, K. M., Lanchbury, J. S. S., Wu, W., Allen, A., Senkus, E., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2154 · Cited by 45
Self-citationNivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
Pouyiourou, M., Kraft, B. N., Wohlfromm, T., Ståhl, M., Kubuschok, B., Löffler, H., Hacker, U. T., Hübner, G., Weiss, L., Bitzer, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42400-5 · Cited by 45
Self-citationZheng, Y., Vioix, H., Liu, F. X., Singh, B., Sharma, S., & Sharda, D. P. (2021) · Future Oncology · doi:10.2217/fon-2021-1040 · Cited by 41
Lemmon, C. A., Zhou, J. H. S., Hobbs, B. P., & Pennell, N. A. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00294 · Cited by 29
Bochtler, T., Reiling, A., Endris, V., Hielscher, T., Volckmar, A., Neumann, O., Kirchner, M., Budczies, J., Heukamp, L. C., Leichsenring, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32882 · Cited by 24
Self-citationAldea, M. D., Tagliamento, M., Bayle, A., Vasseur, D., Vergé, V., Marinello, A., Danlos, F., Blanc‐Durand, F., Bernard, E., Cerbone, L., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00583 · Cited by 24
Self-citationMileshkin, L., Bochtler, T., Pauli, C., Durán-Pacheco, G., Arslan, Ç., Bigot, F., Chalabi, N., Cook, N., Italiano, A., Losa, F., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.006 · Cited by 19
Self-citationDetection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients
Aldea, M. D., Cerbone, L., Bayle, A., Parisi, C., Sarkozy, C., Vasseur, D., Verlingue, L., Blanc‐Durand, F., Mosele, F., Sakkal, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.002 · Cited by 14
Self-citationMolecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program
Vashistha, V., Katsoulakis, E., Guo, A., Price, M. J., Ahmed, S., & Kelley, M. J. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00518 · Cited by 9
Cannon, T. L., Rothe, M., Garrett-Mayer, E. S., Chiu, V. K., Hwang, J. J., Vijayvergia, N., Alese, O. B., Dib, E. G., Duvivier, H. L., Klute, K. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.4_suppl.546 · Cited by 8
Cited by
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Self-citationFrom geroscience to precision geromedicine: Understanding and managing aging
Kroemer, G., Maier, A. B., Cuervo, A. M., Gladyshev, V. N., Ferrucci, L., Gorbunova, V., Kennedy, B. K., Rando, T. A., Seluanov, A., Sierra, F., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.011 · Cited by 395
Hamamoto, R., Koyama, T., Takahashi, S., Yasuda, T., Kobayashi, K., Akagi, Y., Kouno, N., Sudo, K., Hirata, M., Sunami, K., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01781-y · Cited by 8
Metadata
- Authors
- Mosele, M. F., Westphalen, C. B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., Czarnecka, A. M., Meric-Bernstam, F., Michiels, S., Miller, R., Normanno, N., Reis-Filho, J., Remon, J., Robson, M., Rouleau, E., Scarpa, A., Serrano, C., Mateo, J., & André, F.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2024-07
- Volume
- 35
- Issue
- 7
- Pages
- 588-606
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4399036758
- Cited by
- 415
- References
- 171
- FWCI
- 63.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.